AD Diagnostics Molecular Stethoscope is advancing clinical-grade cf-mRNA diagnostics for Alzheimer's disease and dynamic disease management, creating sales opportunities with pharmaceutical developers seeking companion diagnostics and with clinics seeking novel monitoring tools.

Translational Services The company's focus on translational studies and an AI-enabled cf-mRNA platform opens doors for contracted research, data analytics, and biomarker interpretation services for biopharma and CROs looking to accelerate Alzheimer's programs.

Verily Network Joining Verily’s partnered lab ecosystem and adding a strategic board member signals access to a broader collaborator network and pilot opportunities for lab services, co-development, or validation studies.

Early Stage With a small team and a proven proof-of-concept, Molecular Stethoscope is well-positioned to pursue early-stage collaborations, sponsored research, or pilots with biotech and diagnostic players to validate the platform in clinical settings.

Market Alignment The cf-mRNA liquid biopsy approach addresses the rising demand for neurodegenerative disease biomarkers and dynamic patient monitoring, signaling opportunities to partner with larger diagnostics firms and pharma players seeking differentiated Alzheimer's biomarkers.